Theranos' president is leaving the company
Thomson Reuters
On Wednesday, the blood-testing startup said that Sunny Balwani, the company's president and chief operating officer is stepping down and retiring.
Balwani, who joined Theranos in 2009 also served on the company's board of directors.
Theranos will also be bringing in three new members to its board, including biotech veteran Fabrizio Bonanni. The other two - William Foege and Richard Kovacevich - will move over from Theranos' board of counselors.
Before retiring in 2013, Bonanni had been an executive vice president at Amgen, a biopharmaceutical company in Thousand Oaks, California.
Theranos has been embroiled in a controversy ever since a Wall Street Journal report questioned the accuracy of Theranos' tests. Later, an investigation by the Centers for Medicare and Medicaid Services found that Theranos' northern California lab was putting patients in "immediate jeopardy."
Theranos has since stopped running tests out of that lab and has responded to the agency with plans to address its concerns.
The company said in a release that it also plans to reorganize its structure, "with dedicated corporate divisions for Technology and Clinical Operations."
Balwani's departure is the biggest leadership change to the company since its Northern California lab halted all testing. In April, Theranos also announced the addition of a medical advisory board.
- 2 states where home prices are falling because there are too many houses and not enough buyers
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- 9 health benefits of drinking sugarcane juice in summer
- 10 benefits of incorporating almond oil into your daily diet
- From heart health to detoxification: 10 reasons to eat beetroot
- Why did a NASA spacecraft suddenly start talking gibberish after more than 45 years of operation? What fixed it?
- ICICI Bank shares climb nearly 5% after Q4 earnings; mcap soars by ₹36,555.4 crore